Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation

Morusflavone, a flavonoid from Morus alba L., was evaluated for its interactive ability and stability with CYP17A1, in comparison with abiraterone, which is a Food and Drug Administration (FDA)-approved CYP17A1 inhibitor. CYP17A1 inhibition is an important therapeutic target for prostate cancer. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdi, Sayed Aliul Hasan, Ali, Amena, Sayed, Shabihul Fatma, Ahsan, Mohamed Jawed, Tahir, Abu, Ahmad, Wasim, Shukla, Shatrunajay, Ali, Abuzer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468843/
https://www.ncbi.nlm.nih.gov/pubmed/34579444
http://dx.doi.org/10.3390/plants10091912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468843/
https://www.ncbi.nlm.nih.gov/pubmed/34579444
http://dx.doi.org/10.3390/plants10091912

Ejemplares similares